Please assess the completion status of the following clinical trial:

Trial Title: Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* IPF or another fibrotic ILD (including fibrotic NSIP, fibrotic organising pneumoni, and fibrotic hypersensitivity pneumonitis)~* patients aged 18 - 99 yrs~* Desaturation ≤ 88% on a 6MWT on room air~* Stable respiratory symptoms in the 4 weeks preceding the trial including the run in period~Exclusion Criteria:~* Patients meeting criteria for long term oxygen therapy, including hypercapnic patients~* Patients expected to change treatment during the course of the study~* Significant locomotor or communication difficulties and/or severe co-morbidities~* Patients with sarcoidosis or connective tissue disease affecting the musculoskeletal system~* Current smokers~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ambulatory oxygen cylinders (Type: ACTIVE_COMPARATOR): Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
- no oxygen cylinders (Type: NO_INTERVENTION): Subjects randomised to be on air for the first two weeks of the treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).